Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 345

1.

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.

Hart RG, Connolly SJ, Mundl H.

N Engl J Med. 2018 Sep 6;379(10):987. doi: 10.1056/NEJMc1809065. No abstract available.

2.

Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.

Sharma M, Hart RG, Smith EE, Bosch J, Yuan F, Casanova A, Eikelboom JW, Connolly SJ, Wong G, Diaz R, Lopez-Jaramillo P, Ertl G, Störk S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KR, Probstfield JL, Kim JH, Ha JW, O'Donnell M, Vinereanu D, Fox KA, Liang Y, Liu L, Zhu J, Pogosova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Cook Bruns N, Berkowitz S, Yusuf S.

Int J Stroke. 2018 Jul 30:1747493018784478. doi: 10.1177/1747493018784478. [Epub ahead of print]

PMID:
30058959
3.

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.

Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS Investigators.

N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16.

PMID:
29766772
4.

Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.

Kasner SE, Lavados P, Sharma M, Wang Y, Wang Y, Dávalos A, Shamalov N, Cunha L, Lindgren A, Mikulik R, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi R, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni DS, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, DeVries Basson MM, Endres M, Muir K, Bornstein N, Ozturk S, O'Donnell M, Mundl H, Pater C, Weitz J, Peacock WF, Swaminathan B, Kirsch B, Berkowitz SD, Peters G, Pare G, Themeles E, Shoamanesh A, Connolly SJ, Hart RG; NAVIGATE ESUS Steering Committee and Investigators.

J Stroke Cerebrovasc Dis. 2018 Jun;27(6):1673-1682. doi: 10.1016/j.jstrokecerebrovasdis.2018.01.027. Epub 2018 Mar 7.

PMID:
29525076
5.

Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]).

Perera KS, Pearce LA, Sharma M, Benavente O, Connolly SJ, Hart RG; ACTIVE A (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators.

Am J Cardiol. 2018 Mar 1;121(5):584-589. doi: 10.1016/j.amjcard.2017.11.028. Epub 2017 Dec 11.

PMID:
29291887
6.

Embolic Stroke.

Ntaios G, Hart RG.

Circulation. 2017 Dec 19;136(25):2403-2405. doi: 10.1161/CIRCULATIONAHA.117.030509. No abstract available.

PMID:
29255121
7.

Nonmuscle myosin 2 proteins encoded by Myh9, Myh10, and Myh14 are uniquely distributed in the tubular segments of murine kidney.

Otterpohl KL, Hart RG, Evans C, Surendran K, Chandrasekar I.

Physiol Rep. 2017 Dec;5(23). doi: 10.14814/phy2.13513.

8.

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.

Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators.

Lancet. 2017 Nov 10. pii: S0140-6736(17)32409-1. doi: 10.1016/S0140-6736(17)32409-1. [Epub ahead of print]

9.

Should Patients With Ischemic Stroke or Transient Ischemic Attack With Atrial Fibrillation and Microbleeds Be Anticoagulated?

Shoamanesh A, Charidimou A, Sharma M, Hart RG.

Stroke. 2017 Dec;48(12):3408-3412. doi: 10.1161/STROKEAHA.117.018467. Epub 2017 Nov 7. No abstract available.

PMID:
29114097
10.

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators.

N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.

11.

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, Lonn EM, Widimsky P, Hori M, Avezum A, Piegas LS, Bhatt DL, Branch KRH, Probstfield JL, Liang Y, Liu L, Zhu J, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Fox KAA, Kakkar A, Parkhomenko AN, Ertl G, Störk S, Keltai K, Keltai M, Ryden L, Dagenais GR, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Ha JW, Tonkin AM, Varigos JD, Lewis BS, Felix C, Yusoff K, Steg PG, Aboyans V, Metsarinne KP, Anand SS, Hart RG, Lamy A, Moayyedi P, Leong DP, Sharma M, Yusuf S.

Can J Cardiol. 2017 Aug;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001. Epub 2017 Jun 8. Review.

12.

Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions.

Shoamanesh A, Pearce LA, Bazan C, Catanese L, McClure LA, Sharma M, Marti-Fabregas J, Anderson DC, Kase CS, Hart RG, Benavente OR; SPS3 Trial Investigators.

Ann Neurol. 2017 Aug;82(2):196-207. doi: 10.1002/ana.24988. Epub 2017 Jul 19.

13.

Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update.

Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ.

Stroke. 2017 Apr;48(4):867-872. doi: 10.1161/STROKEAHA.116.016414. Epub 2017 Mar 6. Review.

PMID:
28265016
14.

Is There a Role for Betrixaban to Prevent Stroke in Medically Ill Patients?

Quinlan DJ, Eikelboom JW, Hart RG.

Circulation. 2017 Feb 14;135(7):656-658. doi: 10.1161/CIRCULATIONAHA.116.026170. No abstract available.

PMID:
28193799
15.

The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review.

Hess PL, Healey JS, Granger CB, Connolly SJ, Ziegler PD, Alexander JH, Kowey PR, Ruff CT, Flaker G, Halperin JL, Hart RG, Lopes RD.

JAMA Cardiol. 2017 Mar 1;2(3):324-331. doi: 10.1001/jamacardio.2016.5167.

PMID:
28097334
16.

Which Patients With Atrial Fibrillation and Chronic Kidney Disease Should Receive Anticoagulation-And With Which Anticoagulant?

Hart RG, Ingram AJ, Eikelboom JW.

Can J Cardiol. 2017 Feb;33(2):211-213. doi: 10.1016/j.cjca.2016.10.007. Epub 2016 Oct 17. No abstract available.

PMID:
27998618
17.

Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses.

Kilickap M, Bosch J, Eikelboom JW, Hart RG.

Can J Cardiol. 2016 Sep;32(9):1108-16. doi: 10.1016/j.cjca.2016.06.003. Epub 2016 Jun 14. Review.

PMID:
27568871
18.

Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke: Embolic Stroke of Undetermined Source Global Registry.

Perera KS, Vanassche T, Bosch J, Swaminathan B, Mundl H, Giruparajah M, Barboza MA, O'Donnell MJ, Gomez-Schneider M, Hankey GJ, Yoon BW, Roxas A Jr, Lavallee P, Sargento-Freitas J, Shamalov N, Brouns R, Gagliardi RJ, Kasner SE, Pieroni A, Vermehren P, Kitagawa K, Wang Y, Muir K, Coutinho JM, Connolly SJ, Hart RG; ESUS Global Registry Investigators.

Stroke. 2016 Sep;47(9):2197-202. doi: 10.1161/STROKEAHA.116.013378. Epub 2016 Aug 9.

PMID:
27507860
19.

Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study.

O'Donnell MJ, Eikelboom JW, Yusuf S, Diener HC, Hart RG, Smith EE, Gladstone DJ, Sharma M, Dias R, Flaker G, Avezum A, Zhu J, Lewis G, Connolly S.

Am Heart J. 2016 Aug;178:145-50. doi: 10.1016/j.ahj.2016.03.019. Epub 2016 Apr 17.

PMID:
27502862
20.

Stroke: How good is aspirin for patients with acute brain ischaemia?

Hart RG, Eikelboom JW.

Nat Rev Neurol. 2016 Aug;12(8):434-5. doi: 10.1038/nrneurol.2016.97. Epub 2016 Jul 8. Review. No abstract available.

PMID:
27389094

Supplemental Content

Support Center